Physician profile
Scott E Gittins
NPI 1548352131
$5,866.39
in general payments reported to CMS, 2019-2025
11 companies · $641 in 2025
The $641 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $987 · 2021: $851 · 2022: $661 · 2023: $684 · 2024: $895 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,290.76 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $1,353.40 | 2022-2025 | Infuse, Alden Scleral Zenlens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $778.46 | 2019-2020 | |
| Coopervision INC. | $586.56 | 2019-2025 | Myday Contact Lens, Synergeyes Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $480.24 | 2019-2025 | Precision7, Precision 1, Total30 |
| Novartis Pharmaceuticals Corporation | $151.49 | 2021-2022 | |
| Rxsight INC | $113.93 | 2024 | Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Sight Sciences, INC. | $38.92 | 2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Sun Pharmaceutical Industries INC. | $19.45 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $14.38 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Gittins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.